Center on Health Equity & Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Press Releases

Product Approvals and Launches

Video

All Video Types

AJMC TV

Insights

OnLocation

Payer Perspectives

Peer Exchange

Post Conference Perspectives

Stakeholder Summit

Podcasts

Conferences

Conference Coverage

Conference Listing

Journals

All Journals

The American Journal of Managed Care

Population Health, Equity & Outcomes

Evidence-Based Oncology

About Supplements and Featured Publications

Supplements and Featured Publications Issues

Submit a Manuscript

Events

Institute for Value-Based Medicine

Patient-Centered Oncology Care

Resources

Interactive Tools

Clinical Spotlight

Microsites

About AJMC

AJMC Staff

Anniversary

Seema Sonnad Award

Strategic Alliance Partners

Subscribe

Articles

The approval of Amneal Pharmaceuticals’ generic version of rifaximin 550 mg oral tablets is tentative due to the product’s involvement in litigation.

FDA Grants Tentative Approval to Generic Version of Rifaximin for IBS-D

Skylar is an associate editor for The American Journal of Managed Care® (AJMC®) and The Center for Biosimilars®, and joined AJMC® in 2020. She is responsible for covering all aspects of the ever-changing global biosimilar industry and produces content that is accessible and informative for all health care stakeholders.

She has a BA in journalism and media studies from Rutgers University. You can connect with Skylar on 

The American Gastroenterology Association (AGA) updated its clinical practice guidelines for managing hepatitis B reactivation (HBVr) in at-risk individuals, recommending antiviral prophylaxis for high- and moderate-risk patients.

New AGA Guidelines Recommend Risk-Based Prophylaxis for Hepatitis B Reactivation Monitoring

Videos

Gladys Antelo-Allen of Camden Coalition discusses a new skills lab offering accessible learning modules with 12 microlessons on best practices for approaching complex care. 

Developing Skills for Authentic Healing Relationships in Complex Care: Gladys Antelo-Allen

Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted therapy. 


FDA Approves First HER2-Ultralow Companion Diagnostic, Expanding Treatment Eligibility

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About

Contact

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

Twitter

LinkedIn

Instagram

Specialty Area

Biosimilars

Cardiorenalmetabolic

Dermatology

Gastroenterology

Hematology

Hepatology

Immunology

Infectious Disease

MASH

Mental Health

Neurology

Obesity

Oncology

Ophthalmology

Pulmonology

Rare Disease

Respiratory

Rheumatology

Women's Health

Spotlight

Free In-Person Regional Events Focused on Oncology and Population Health

Topics

Digital Health

Formulary

Gene Therapy

Guidelines

Health Care Administration

Population Health

All Coverage

Event Coverage

Interviews

AJMC Journals

Author Forms

Authors

Nominate a Rising Leader

View

Employing Effective Multidisciplinary Care to Reduce the Burden of Myelodysplastic Syndrome 

Video Series

Key opinion leaders discuss the process of adapting MDS treatment strategies for optimal impact of care.

Adapting MDS Treatment Approach 

A panel of medical experts discuss the significance of collaborative care and key considerations in the treatment of myelodysplastic syndrome (MDS).

Ryan Haumschild, PharmD, MS, MBA, CPEL, opens the discussion by defining the MDS disease state. 

Myelodysplastic Syndrome (MDS) Overview 

An expert perspective on the variety of MDS subtypes is provided. 

Distinguishing Between Different MDS Subtypes 

Key opinion leaders discuss how patient quality of life is impacted by MDS treatment-associated challenges.

MDS-Related Complications Impacting Patient Quality of Life

Financial considerations in MDS treatment are discussed.

Economic Implications of MDS Management

Dr Haumschild leads a discussion surrounding the latest advancements in treatment algorithms for myelodysplastic syndrome.

Examining Treatment Algorithms for MDS 

Considerations for growth factor and stem cell transplant for patients with MDS is discussed. 

Growth Factor and Stem Cell Transplant Candidacy in MDS

A panel of experts discusses how novel agents are impacting the treatment landscape for patients diagnosed with MDS. 

Novel Agents Contributing to Evolving MDS Therapy Strategies 

Treatment compliance impacted by oral versus IV therapy is evaluated. 

Benefits of Oral Therapies In MDS Treatment Adherence 

Novel therapies in MDS treatment are evaluated by a panel of experts led by Dr Haumschild.

Novel Therapy Impact on Patient Quality of Life

Experts discuss how collaborative care drives optimal MDS treatment.

Multidisciplinary Care Driving Effective MDS Treatment

The panelists highlight key takeaways for payors involved in MDS treatment. 

Payor Considerations In MDS Management

Potential issues associated with insurance coverage and ways to navigate these challenges are discussed by medical experts.

Navigating Insurance-Related Challenges Associated With MDS Treatment

The panelists provide their final takeaways from the discussion surrounding treatment of MDS.

Key Considerations Surrounding MDS Treatment

Adapting MDS Treatment Approach

EP: 1.Myelodysplastic Syndrome (MDS) Overview

EP: 2.Distinguishing Between Different MDS Subtypes

EP: 3.MDS-Related Complications Impacting Patient Quality of Life

EP: 4.Economic Implications of MDS Management

EP: 5.Examining Treatment Algorithms for MDS

EP: 6.Growth Factor and Stem Cell Transplant Candidacy in MDS

EP: 7.Novel Agents Contributing to Evolving MDS Therapy Strategies

EP: 8.Benefits of Oral Therapies In MDS Treatment Adherence

EP: 9.Adapting MDS Treatment Approach

EP: 10.Novel Therapy Impact on Patient Quality of Life

EP: 11.Multidisciplinary Care Driving Effective MDS Treatment

EP: 12.Payor Considerations In MDS Management

EP: 13.Navigating Insurance-Related Challenges Associated With MDS Treatment

EP: 14.Key Considerations Surrounding MDS Treatment